Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Kazia Therapeutics Ltd ADR (KZIA)

Kazia Therapeutics Ltd ADR (KZIA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,516
  • Shares Outstanding, K 1,653
  • Annual Sales, $ 1,230 K
  • Annual Income, $ -13,410 K
  • EBIT $ 0 M
  • EBITDA $ -9 M
  • 60-Month Beta 1.67
  • Price/Sales 489.90
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.65 +13.83%
on 12/23/25
17.40 -56.49%
on 12/08/25
-2.39 (-24.00%)
since 11/26/25
3-Month
5.58 +35.69%
on 11/18/25
17.40 -56.49%
on 12/08/25
+0.24 (+3.27%)
since 09/26/25
52-Week
2.86 +164.69%
on 04/17/25
17.40 -56.49%
on 12/08/25
-7.53 (-49.87%)
since 12/26/24

Most Recent Stories

More News
Kazia Therapeutics Regains Full Nasdaq Listing Compliance

Restoration of Nasdaq compliance follows $50 million institutional financing and reinforces balance-sheet strength

KZIA : 7.57 (-5.37%)
Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+

First patient from TNBC trial demonstrated 76% tumor volume shrinkage with corresponding reductions in circulating tumor cells (CTC) and clusters

KZIA : 7.57 (-5.37%)
Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities

SYDNEY , Dec. 2, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) , an oncology-focused drug development company, today announced that it has entered into a securities purchase...

KZIA : 7.57 (-5.37%)
Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy

SYDNEY , Nov. 18, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (Nasdaq: KZIA), an oncology-focused drug development company, today announced that a patient with stage IV triple-negative breast...

KZIA : 7.57 (-5.37%)
Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner

SYDNEY , Oct. 27, 2025 /PRNewswire/ -- Kazia Therapeutics Limited ("Kazia" or the "Company") today announced its intention to request and hold a follow-up Type C meeting with the U.S. Food & Drug...

KZIA : 7.57 (-5.37%)
Kazia Therapeutics Partners with QIMR Berghofer for Innovative PD-L1 Degrader Program

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Kazia Therapeutics...

KZIA : 7.57 (-5.37%)
Immunotherapy Breakthroughs Propel Clinical Momentum Ahead of ESMO Congress

Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – Researchers at Ohio State University just unlocked why many cancer immunotherapies fail, identifying a protein...

KZIA : 7.57 (-5.37%)
CELC : 102.25 (-0.35%)
GRAL : 91.59 (-0.29%)
BOLT : 5.33 (+2.50%)
GTBP : 0.8324 (-1.49%)
KZA.AX : 0.080 (+9.59%)
Kazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader Program

SYDNEY , Oct. 7, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced an exclusive collaboration and in-licensing agreement...

KZIA : 7.57 (-5.37%)
Kazia Therapeutics Reports Significant Tumor Reduction in TNBC Patient with Paxalisib

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Kazia Therapeutics...

KZIA : 7.57 (-5.37%)
Kazia Therapeutics Announces 86% Reduction in Tumor Burden in Expanded-Access Case of Metastatic TNBC Patient Treated with Paxalisib-Immunotherapy Regimen

SYDNEY , Oct. 2, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today reported a substantial reduction in tumor burden from...

KZIA : 7.57 (-5.37%)

Business Summary

Kazia Therapeutics Limited is an oncology-focused biotechnology company. It develops anti-cancer drugs as well as provides pharmaceutical research and development technology solutions. The company's lead program is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being...

See More

Key Turning Points

3rd Resistance Point 8.91
2nd Resistance Point 8.62
1st Resistance Point 8.10
Last Price 7.57
1st Support Level 7.28
2nd Support Level 6.99
3rd Support Level 6.47

See More

52-Week High 17.40
Fibonacci 61.8% 11.85
Fibonacci 50% 10.13
Fibonacci 38.2% 8.41
Last Price 7.57
52-Week Low 2.86

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar